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Background: BALKAN-AF evaluated patterns of atrial fibrillation (AF) management in real-world clinical
practice in the Balkans. The objectives were: to assess the proportion of patients with first-diagnosed
AF in the BALKAN-AF cohort and to compare the management of patients with newly-diagnosed AF
and those with previously known AF in clinical practice.
Methods: Consecutive patients from 7 Balkan countries were enrolled prospectively to the snapshot
BALKAN-AF survey.
Results: Of 2712 enrolled patients, 2677 (98.7%) with complete data were included. 631 (23.6%) patients
had newly-diagnosed AF and 2046 (76.4%) patients had known AF. Patients with newly-diagnosed AF
were more likely to be hospitalized for AF and to receive single antiplatelet therapy (SAPT) alone and less
likely to receive OACs than those with known AF (all p < 0.001). The use of OAC was not significantly asso-
ciated with the CHA2DS2-VASc (p = 0.624) or HAS-BLED score (p = 0.225) on univariate analysis.
Treatment in capital city, hypertension, dilated cardiomyopathy, mitral valve disease, country of resi-
dence or rate control strategy were independent predictors of OAC use, whilst non-emergency centre,
treatment by cardiologist, paroxysmal AF, palpitations, symptoms attributable to AF (as judged by physi-
cian), mean heart rate and AF as the main reason for hospitalization were independent predictors of
rhythm control strategy use.
Conclusions: In BALKAN-AF survey, patients with newly-diagnosed AF were more often hospitalized, less
often received OAC and were more likely to receive SAPT alone. The use of OAC for stroke prevention has
not been driven by the individual patient stroke risk.
 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Atrial fibrillation (AF) is the most prevalent sustained cardiac
arrhythmia in adults [1]. Owing to its significant association with
cardiovascular morbidity and mortality, AF portends significant
burden to the patients and healthcare systems worldwide [2,3].
Guideline-adherent management of AF has been associated with
improved patients’ outcomes [4–6], but contemporary observa-
tional registry-based data showed variable proportion of
guideline-adherent management of AF in clinical practice in differ-
ent world regions [7–12].
Patients with newly-diagnosed AFmay have different prevailing
risk profiles and outcomes in comparison to those with a history of
paroxysmal, persistent, long-term persistent or permanent AF
[13,14]. In a large international observational registry-based study,
for example, the rates of all-causemortality, stroke/systemic embo-
lism andmajor bleeding during a 2-year follow-upwere the highest
within the first 4 months since new-onset AF was diagnosed [15].
This emphasizes the importance of timely initiation of AF treatment
and AF comprehensive care early after the diagnosis of AF has been
made. Moreover, physicians should be aware of warning signs of
possible early cardiovascular mortality [16].
Contemporary large international AF registries included vari-
able proportion of patients with newly-diagnosed AF, but countries
in the Balkan region (encompassing approximately 50 million
inhabitants) were largely underrepresented in these registries
[17]. A prospective survey conducted in seven Balkan countries
showed a fairly good overall use of oral anticoagulant therapy
(OAC) for AF-related stroke prevention (73.5%), but the use of
OAC was poorly related to the individual stroke risk [18].
The aims of this study were as follows: (i) to assess the propor-
tion of patients with first-diagnosed AF in the BALKAN-AF cohort;
and (ii) to compare the management of patients with newly-
diagnosed AF and those with previously known AF in routine clin-
ical practice in patients with newly-diagnosed AF in seven Balkan
countries.2. Methods
The design of BALKAN-AF survey has been previously published
[17]. The BALKAN-AF registry was designed to prospectively collect
real-world data regarding consecutive patients with electrocardio-
graphically documented ‘non-valvular’ AF. Patients were managed
by a cardiologist or an internal medicine specialist where cardiol-
ogist was not available. Patients were enrolled by university and
non-university hospitals and outpatient health centres in Albania,
Bosnia & Herzegovina, Bulgaria, Croatia, Montenegro, Romania
and Serbia.
This multicentre, observational, snapshot survey was designed
and conducted by the Serbian Atrial Fibrillation Association (SAFA).
The registry was introduced to the National Cardiology Societies/
relevant Working Groups in particular Balkan countries and
approved by the National and/or local Institutional Review Board.
A signed patient informed consent form was acquired before enrol-
ment. The study protocol corresponds with the ethical guidelines
of the 1975 Declaration of Helsinki.
Patients with prosthetic mechanical heart valves, moderate or
severe mitral stenosis or any significant valvular disease requiring
surgical treatment and those aged <18 years were excluded from
the study.
Data were collected using an electronic case report form
designed by SAFA. Following information was obtained: patients’
and AF-related characteristics, health care setting, patient’s physi-
cal findings and management at enrolling visit, diagnostic proce-
dures related to AF at enrolling visit and/or in previous12 months and AF treatment at discharge. Stroke risk was assessed
according to CHA2DS2-VASc (congestive heart failure, hyperten-
sion, age 75 years, diabetes, stroke/transient ischemic attack
(TIA), vascular disease, age 65–74 years, sex category) score [19].
Bleeding risk was evaluated according to HAS-BLED (hypertension,
abnormal renal/liver function, stroke, bleeding history or predispo-
sition, labile International Normalised Ratio (INR), elderly
(>65 years), drugs or alcohol concomitantly) score [19].
Systematic monitoring of centres and follow-up visits were not
conducted. National coordinators and participating investigators
were responsible for the consecutiveness of enrolled patients and
correctness and completeness of entered data.
2.1. Statistical analysis
Categorical variableswere presented as absolute frequencies and
percentages, and continuous variables as mean and standard devia-
tion (SD). Comparison of categorical variableswith normal distribu-
tion was performed using Student’s t-test. Continuous variables
with skewed distribution were compared with Mann-Whitney test.
The descriptive analysis included baseline characteristic of patients
with newly-diagnosed AF and those with previously known AF. The
association of patient-, AF- and healthcare system-related variables
with the management of patients with newly-diagnosed AF was
evaluated using univariate logistic regression analyses. The vari-
ables with statistically significant association on univariate logistic
regression analysis were entered into multivariable logistic regres-
sionmodels to identify multivariable predictors of AFmanagement.
Results are expressed as odds ratio (OR) with 95% confidence inter-
val (CI). A two-sided p value of less than 0.05was interpreted as sta-
tistically significant. All analyses were performed using SAS
software version 9.4 (SAS Institute, Inc., Cary, NC, USA).
3. Results
Of 2712 patients enrolled in seven participating Balkan coun-
tries, complete data required for this analysis were available for
2677 patients (98.7%). Of these, 631 patients (23.6%) had first-
diagnosed AF and 2046 (76.4%) had a history of AF (Table 1).
3.1. Demographic and AF-related characteristics
Patients with newly-diagnosed AF were younger, more often
had paroxysmal AF and more commonly had symptoms attributa-
ble to AF (as judged by the responsible physician/investigator),
with higher mean European Heart Rhythm Association (EHRA)
symptom score (all p < 0.001) than patients with history of AF
(Table 1).
3.2. Physical findings and comorbidity
Patients with newly-diagnosed AF had significantly higher
mean heart rate (103.4 ± 33.4 versus 87.4 ± 25.5 beats per minute
[bpm], p < 0.001) and less comorbidity (all p < 0.05) than those
with a known AF (Table 2).
3.3. Stroke and bleeding risk factors
Mean CHA2DS2-VASc score was lower in newly-diagnosed AF
patients than in the previously known AF group (3.0 ± 1.8 vs
3.4 ± 1.9, p < 0.001), and the prevalence of patients with truly
low risk of stroke (a CHA2DS2-VASc of 0 in males or 1 in females)
was higher in the newly-diagnosed AF group (p = 0.006).
The risk of bleeding (i.e., mean HAS-BLED score) was lower in
patients with first-diagnosed AF in comparison to those with a pre-
Table 1
Demographic and atrial fibrillation-related characteristics.
Variable All
N = 2677
First-diagnosed AF
N = 631 (23.6%)
History of AF
N = 2046 (76.4%)
P value
Mean age (years) 69.1 ± 10.9 67.5 ± 12.1 69.6 ± 10.5 <0.001
Male sex 1485 (55.5) 348 (55.2) 1137 (55.6) 0.852
Paroxysmal AF 960 (35.9) 403 (63.9) 557 (27.2) <0.001
Asymptomatic AF 572 (21.4) 64 (10.1) 508 (24.8) <0.001
Symptoms
Palpitations 1229 (45.9) 406 (64.3) 823 (40.2) <0.001
Chest pain 644 (24.1) 205 (32.5) 439 (21.5) <0.001
Shortness of breath 1278 (47.7) 297 (47.1) 981 (47.9) 0.667
Dizziness 435 (16.2) 103 (16.3) 332 (16.2) 0.970
Syncope 120 (4.5) 42 (6.7) 78 (3.8) 0.003
Fatigue 1074 (40.1) 218 (34.5) 856 (41.8) 0.001
General non-wellbeing 615 (23.0) 158 (25.0) 457 (22.3) 0.166
Fear/anxiety 267 (10.0) 78 (12.4) 189 (9.2) 0.023
Symptoms attributable to AF* 802 (30.0) 311 (49.3) 491 (24.0) <0.001
EHRA Symptom score (mean) 2.2 ± 0.8 2.4 ± 0.8 2.0 ± 0.8 <0.001
EHRA I 571 (21.3) 64 (10.1) 507 (24.8) <0.001
EHRA II 1254 (46.8) 294 (46.6) 960 (46.9) 0.852
EHRA III 712 (26.6) 218 (34.5) 494 (24.1) <0.001
EHRA IV 140 (5.2) 56 (8.9) 84 (4.1) <0.001
AF: Atrial fibrillation, EHRA: European Heart Rhythm Association.
* As judged by the responsible physician/investigator.
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proportion of patients with a HAS-BLED  3 was higher in the lat-
ter subgroup (p < 0.001), Table 2.
Country-specific stroke and bleeding risk distribution is pre-
sented in Fig. 1.
3.4. AF management settings and diagnostic assessment
Most participants were seen by a cardiologist in an academic
healthcare facility (Table 3). However, patients with newly-
diagnosed AF were less commonly enrolled during an outpatient
visit (n = 101, 16.0% vs n = 616, 30.1%) and AF was more often
the main reason for the hospitalization (n = 369, 58.5% vs
n = 968, 47.3%) compared with patients with previously known
AF (both p < 0.001). There were no significant differences in the
diagnostic assessment at enrolling visit between patients with
newly-diagnosed versus previously known AF (Table 3).
3.5. Stroke prevention strategies
Overall, OAC was used in 376 (59.6%) of patients with first-
diagnosed AF and 1589 (77.7%) of those with previously diagnosed
AF (p < 0.001), Table 3. The use of OAC alone was more prevalent
among patients with previously diagnosed AF (n = 1348, 65.9% vs
n = 293, 46.4%), who were also more often prescribed a vitamin
K antagonist (VKA) in comparison to patients with newly-
diagnosed AF (n = 1336, 65.3% vs. n = 291, 46.1%), both
p < 0.001. Single antiplatelet therapy alone and triple antithrom-
botic therapy were used more often in first-diagnosed AF patients
than in those with a history of AF (p < 0.001, p = 0.012, respec-
tively), Table 3. Of patients with newly-diagnosed AF and CHA2-
DS2-VASc score 2, 46% received OAC only, whereas 38%
received stroke prevention other than OAC or had no antithrom-
botic therapy (Fig. 2).
Country-specific stroke prevention strategies are presented in
Table 4.
3.6. Arrhythmia-directed management strategies
Rhythm control strategy was more often used in first-diagnosed
AF patients (n = 322, 51.0% versus n = 578, 28.3%), whereas rate
control as the main treatment strategy was more commonly usedin those with previously known AF (n = 1357, 66.3% versus
n = 265, 42.0%), both p < 0.001. Catheter ablation and atrioventric-
ular node ablation with pacemaker implantation were not per-
formed in first-diagnosed AF patients.
Digoxin was used in 107 (17.0%) of patients with newly-
diagnosed AF and in 548 (26.8%) of patients with known AF
(p < 0.001). Amiodarone was prescribed in 224 (35.5%) of patients
with a new diagnosis of AF and in 438 (21.4%) of patients with pre-
viously diagnosed AF (p < 0.001) (Table 3). There were no signifi-
cant differences in use of other agents for rhythm and rate
control (Table 3).
3.7. Other therapies
Loop diuretics were used in 199 (31.5%) of newly-diagnosed AF
group and in 921 (45.0%) of group with previously-diagnosed AF
(p < 0.001) (Table 3). The use of other drugs is shown in Table 3.
3.8. Determinants of OAC use in patients with newly-diagnosed AF
The use of OAC was not significantly associated with the CHA2-
DS2-VASc (OR 1.02; 95%CI, 0.93–1.11, p = 0.624) or HAS-BLED score
(OR 1.10, 95% CI 0.94–1.28, p = 0.225) on univariate analysis (see
the Online supplement).
On multivariable analysis adjusted for country of residence,
patients treated in the capital city, those with hypertension, dilated
cardiomyopathy (DCM) or mitral valve disease and patients
assigned to rate control strategy were more likely to receive OAC,
whereas treatment in a non-emergency centre, paroxysmal AF
and history of previous bleeding event were associated with
decreased likelihood of OAC use (Table 5). Of note, OAC use was
positively associated with the residence in Romania.
3.9. Predictors of rhythm control strategy in patients with newly-
diagnosed AF
Non-emergency centre, treatment by cardiologist, paroxysmal
AF, palpitations, symptoms attributable to AF (as judged by the
responsible physician/investigator), mean heart rate and AF as
the main reason for hospitalization (all p < 0.05) were independent
predictors of the increased use of rhythm control strategy in
patients with first-diagnosed AF, whereas fatigue, HF, DCM, mitral
Table 2
Physical findings, comorbidities, stroke and bleeding risk factors and baseline stroke and bleeding risk profile.
Variable All
N = 2677
First-diagnosed AF
N = 631 (23.6%)
History of AF
N = 2046 (76.4%)
P value
SBP (mean, mmHg) 134.6 ± 22.0 135.8 ± 23.2 134.2 ± 21.6 0.107
DBP (mean, mmHg) 81.0 ± 12.2 81.9 ± 12.8 80.7 ± 12.1 0.038
Heart rate (mean, bpm) 91.2 ± 28.4 103.4 ± 33.4 87.4 ± 25.5 <0.001
NYHA class (mean) 1.8 ± 1.0 1.6 ± 0.9 1.8 ± 1.0 <0.001
NYHA I 1569 (58.6) 424 (67.2) 1145 (56.0) <0.001
NYHA II 378 (14.1) 89 (14.1) 289 (14.1) 0.975
NYHA III 532 (19.9) 97 (15.4) 435 (21.3) 0.001
NYHA IV 198 (7.4) 22 (3.5) 176 (8.6) <0.001
CHA2DS2-VASc risk factors
HF 1163 (43.4) 173 (27.4) 990 (48.4) <0.001
CHF or LVEF < 40% 1343 (50.2) 254 (40.3) 1089 (53.2) <0.001
Hypertension 2121 (79.2) 469 (74.3) 1652 (80.7) <0.001
Age 75 years 947 (35.4) 211 (33.4) 736 (36.0) 0.356
Diabetes mellitus 668 (25.0) 150 (23.8) 518 (25.3) 0.449
Prior stroke/TIA/SE 386 (14.4) 59 (9.4) 327 (16.0) <0.001
Vascular disease* 568 (21.2) 131 (20.8) 437 (21.4) 0.879
Age 65–74 years 882 (32.9) 181 (28.7) 701 (34.3) 0.017
Female sex 1192 (44.5) 283 (44.8) 909 (44.4) 0.852
CHA2DS2-VASc (mean) 3.3 ± 1.9 3.0 ± 1.8 3.4 ± 1.9 <0.001
CHA2DS2-VASc 0 (males) or 1 (females) 162 (6.1) 52 (8.2) 110 (5.4) 0.006
CHA2DS2-VASc 1 289 (10.8) 83 (13.2) 206 (10.1) 0.021
CHA2DS2-VASc  2 2302 (86.0) 512 (81.1) 1790 (87.5) <0.001
HAS-BLED risk factors
Uncontrolled hypertension 683 (25.5) 178 (28.2) 505 (24.7) 0.002
CKD 411 (15.4) 78 (12.4) 333 (16.3) 0.024
Liver disease 96 (3.6) 31 (4.9) 65 (3.2) 0.039
Prior bleeding 133 (6.5) 17 (2.7) 116 (5.7) 0.003
Age 65 years 1829 (68.3) 392 (62.1) 1437 (70.2) <0.001
Aspirin use 688 (25.7) 244 (38.7) 444 (21.7) <0.001
Excessive alcohol intake 110 (4.1) 38 (6.0) 72 (3.5) 0.004
HAS-BLED (mean) 1.9 ± 1.2 1.6 ± 1.0 2.1 ± 1.3 <0.001
HAS-BLED  3 823 (30.7) 105 (16.6) 718 (35.1) <0.001
Other comorbidities
CAD 821 (30.7) 195 (30.9) 626 (30.6) 0.877
Prior MI 369 (13.8) 88 (13.9) 281 (13.7) 0.967
Prior CABG 100 (3.7) 16 (2.5) 84 (4.1) 0.078
Prior PCI/stenting 225 (8.4) 69 (10.9) 156 (7.6) 0.004
PAD 122 (4.6) 18 (2.9) 104 (5.1) 0.019
Carotid artery disease 56 (2.1) 7 (1.1) 49 (2.4) 0.499
Dilated cardiomyopathy 216 (8.1) 25 (4.0) 191 (9.3) <0.001
HCM 53 (2.0) 10 (1.6) 43 (2.1) 0.441
Mitral valve disease 845 (31.6) 149 (23.6) 696 (34.0) <0.001
Aortic valve disease 300 (11.2) 56 (8.9) 244 (11.9) 0.044
CIED 159 (5.9) 16 (2.5) 143 (7.0) <0.001
COPD 342 (12.8) 74 (11.7) 268 (13.1) 0.368
Obstructive sleep apnoea 53 (2.0) 18 (2.9) 35 (1.7) 0.072
Thyroid dysfunction 276 (10.3) 54 (8.6) 222 (10.9) 0.102
Malignancy 119 (4.4) 19 (3.0) 100 (4.9) 0.047
Dementia 71 (2.7) 20 (3.2) 51 (2.5) 0.353
Dyslipidaemia 1020 (38.1) 236 (37.4) 784 (38.3) 0.673
Anaemia 373 (13.9) 83 (13.2) 290 (14.2) 0.522
SBP: systolic blood pressure; DBP: diastolic blood pressure; bpm: beats per minute, NYHA: New York Heart Association; CAD: coronary artery disease; CKD, chronic kidney
disease, MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; PAD: peripheral artery disease; CIED: cardiac
implantable electronic device; CHA2DS2-VASc: congestive heart failure, hypertension, age 75 years, diabetes, stroke/transient ischemic attack (TIA), vascular disease, age
65–74 years, sex category, COPD: chronic obstructive pulmonary disease, HF: heart failure, CHF: congestive heart failure; HAS-BLED: hypertension, abnormal renal/liver
function, stroke, bleeding history or predisposition, labile International Normalised Ratio, elderly (age >65 years), drugs or alcohol concomitantly, LVEF: left ventricular
ejection fraction; TIA: Transient ischemic attack; SE: Systemic embolism; INR: International normalized ratio, HCM, hypertrophic cardiomyopathy.
* Vascular disease was defined as prior MI, complex aortic plaque or peripheral artery disease.
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associated with the use of rhythm control strategy in patients with
first-diagnosed AF (Table 5).4. Discussion
In the present prospective, multicentre, observational survey of
consecutive in- or outpatients with AF, approximately one out of 4
patients had a first-diagnosed AF. The prevalence of first-diagnosed
AF in the BALKAN-AF survey was close to that in one ‘real-world’European registry [10]. However, the proportion of patients with
newly-diagnosed AF ranged from 5.0% to 30.3% in the AF registries
[10,20–22]. The present analysis provides novel insights into clin-
ical practice form the largest published prospective AF dataset
from the Balkans, a European region that has been under-
represented in many prior clinical trials or registries.
The main findings of our study were as follows: (i) different
demographic, cardiovascular risk and AF-related profile of patients
with first-diagnosed AF in comparison to those with previously
known AF (the former were younger, with less comorbidity and
Fig. 1. Stroke and bleeding risk in patients with newly-diagnosed AF. AF, atrial fibrillation, B&H, Bosnia & Herzegovina, CHA2DS2-VASc; congestive heart failure,
hypertension, age 75 years, diabetes, stroke/transient ischemic attack (TIA), vascular disease, age 65–74 years, sex category, HAS-BLED: hypertension, abnormal renal/liver
function, stroke, bleeding history or predisposition, labile International Normalised Ratio, elderly (age >65 years), drugs or alcohol concomitantly.
M. Kozieł et al. / IJC Heart & Vasculature 26 (2020) 100461 5lower stroke and bleeding risk, but more symptomatic and more
likely to have paroxysmal AF), (ii) differences in the management
of AF – patients with first-diagnosed AF were more often hospital-Table 3
Atrial fibrillation management.
Variable All
N = 2677
AF management settings
AF was the main reason for the hospitalization 1337 (49.9)
Outpatient visit 717 (26.8)
Academic healthcare facility 2161 (80.7)
AF managed by a cardiologist 2147 (80.2)
Diagnostic assessment
Routine biochemistry 2171 (81.1)
Thyroid hormones measurement 943 (35.2)
Transthoracic echocardiography 2147 (80.2)
No additional diagnostic assessment 1479 (55.2)
Holter monitoring (rhythm) 708 (26.4)
Stroke prevention (at enrolment)
No antithrombotic therapy 265 (9.9)
Overall OAC 1965 (73.4)
OAC alone 1641 (61.3)
VKA 1627 (60.8)
NOAC 338 (12.6)
Single antiplatelet therapy alone 321 (12.0)
DAPT alone 120 (4.5)
Dual antithrombotic therapy 241 (9.0)
Triple antithrombotic therapy 83 (3.1)
Symptom management
Rhythm control 900 (33.6)
Rate control 1622 (60.6)
Non-pharmacological AF therapies (at enrolment or in the future)
AF catheter ablation 60 (2.2)
AV node ablation with PM implantation 10 (0.4)
Pharmacological AF therapies (at enrolment)
Digoxin 655 (24.5)
Verapamil/Diltiazem 130 (4.9)
Beta blockers 1961 (73.3)
Propafenone/Flecainide 250 (9.3)
Sotalol 21 (0.8)
Amiodarone 662 (24.7)
Other therapy (at enrolment)
ACEi 1264 (47.2)
AT1 receptor blockers 517 (19.3)
Loop diuretics 1120 (41.8)
Statins 1108 (41.4)
AF: atrial fibrillation; OAC: oral anticoagulant therapy; NOAC: non-vitamin K antagonis
tricular; ACEi: angiotensin converting enzyme inhibitor; AT1: angiotensin receptor, DAPized for AF, less often received OAC but were more likely to receive
single antiplatelet therapy alone, and more often were treated with
a rhythm control strategy, (iii) the use of OAC for stroke preventionFirst-diagnosed AF
N = 631
Previously diagnosed AF
N = 2046
P value
369 (58.5) 968 (47.3) <0.001
101 (16.0) 616 (30.1) <0.001
467 (74.0) 1694 (82.8) <0.001
505 (80.0) 1642 (80.3) 0.602
523 (82.9) 1648 (80.5) 0.115
235 (37.2) 708 (34.6) 0.212
520 (82.4) 1627 (79.5) 0.088
367 (58.2) 1112 (54.3) 0.086
157 (24.9) 551 (26.9) 0.314
75 (11.9) 190 (9.3) 0.051
376 (59.6) 1589 (77.7) <0.001
293 (46.4) 1348 (65.9) <0.001
291 (46.1) 1336 (65.3) <0.001
85 (13.5) 253 (12.4) 0.437
120 (19.0) 201 (9.8) <0.001
56 (8.9) 64 (3.1) <0.001
54 (8.6) 187 (9.1) 0.682
29 (4.6) 54 (2.6) 0.012
322 (51.0) 578 (28.3) <0.001
265 (42.0) 1357 (66.3) <0.001
0 (0) 60 (2.9) <0.001
0 (0) 10 (0.5) <0.001
107 (17.0) 548 (26.8) <0.001
23 (3.6) 107 (5.2) 0.452
449 (71.2) 1512 (73.9) 0.242
62 (9.8) 188 (9.2) 0.368
3 (0.5) 18 (0.9) 0.319
224 (35.5) 438 (21.4) <0.001
282 (44.7) 982 (48.0) 0.179
103 (16.3) 414 (20.2) 0.034
199 (31.5) 921 (45.0) <0.001
260 (41.2) 848 (41.4) 0.993
t oral anticoagulant; ECV: electrical cardioversion; PM: pacemaker; AV: atrioven-
T: dual antiplatelet therapy.
Fig. 2. The prevalence of stroke prevention strategies by CHA2DS2-VASc and HAS-BLED risk strata. CHA2DS2-VASc; congestive heart failure, hypertension, age 75 years,
diabetes, stroke/transient ischemic attack (TIA), vascular disease, age 65–74 years, sex category, DAPT, dual antiplatelet therapy, HAS-BLED: hypertension, abnormal renal/
liver function, stroke, bleeding history or predisposition, labile International Normalised Ratio, elderly (age >65 years), drugs or alcohol concomitantly, OAC, oral
anticoagulants, SAPT, single antiplatelet therapy.
Table 4
Country-specific distribution of stroke prevention strategies in patients with first-diagnosed AF.
Albania
n = 108
Bosnia & Herzegovina
n = 92
Bulgaria
n = 110
Croatia
n = 23
Montenegro
n = 22
Romania
n = 146
Serbia
n = 131
No antithrombotic therapy (%) 6 (5.6) 13 (14.1) 18 (16.4) 3 (13.0) 2 (9.1) 13 (8.9) 20 (15.3)
Overall OAC (%) 66 (61.1) 31 (33.7) 60 (54.5) 15 (6.5) 16 (72.7) 105 (71.9) 83 (63.4)
OAC alone (%) 39 (36.1) 29 (31.5) 52 (47.3) 14 (6.1) 9 (40.9) 88 (60.3) 62 (47.3)
VKAs (%) 57 (52.8) 26 (28.3) 27 (24.5) 14 (6.1) 14 (63.6) 91 (62.3) 62 (47.3)
NOACs (%) 9 (8.3) 5 (5.4) 33 (30.0) 1 (4.3) 2 (9.1) 14 (9.6) 21 (16.0)
SAPT (%) 17 (15.7) 37 (40.2) 24 (21.8) 2 (8.7) 3 (13.6) 15 (10.3) 22 (16.8)
DAPT (%) 18 (16.7) 11 (12.0) 7 (6.4) 1 (4.3) 1 (4.5) 13 (8.9) 5 (3.8)
Dual therapy (%) 17 (15.7) 2 (2.2) 5 (4.5) 1 (4.3) 4 (18.1) 10 (6.8) 15 (11.4)
Triple therapy (%) 10 (9.3) 0 (0.0) 3 (2.7) 0 (0.0) 3 (13.6) 7 (4.8) 6 (4.6)
AF, atrial fibrillation, DAPT, dual antiplatelet therapy, OAC, oral anticoagulants, NOAC, non-vitamin K oral anticoagulants, SAPT, single antiplatelet therapy, VKA, vitamin K
antagonists
Table 5
Independent predictors of the use of OAC (alone or in combination) and use of rhythm control strategy in patients with first-diagnosed AF.
Predictors of use of OAC
Multivariate analysis
OR 95% CI p-Value
Capital city 1.96 1.36–2.81 <0.001
Non-emergency centre 0.39 0.24–0.65 <0.001
Paroxysmal AF 0.22 0.15–0.33 <0.001
Hypertension 2.20 1.48–3.26 <0.001
DCM 11.97 1.59–90.17 0.016
Mitral valve disease 1.66 1.09–2.53 0.017
Bleeding events 0.21 0.06–0.70 0.011
Rate control 1.70 1.20–2.40 0.003
Countries:
Bosnia & Herzegovina 0.39 0.23–0.67 0.001
Romania 1.79 1.15–2.79 0.010
Predictors of use of rhythm control strategy
Multivariate analysis
OR 95% CI p-Value
Non-emergency centre 2.06 1.25–3.37 0.004
AF main reason for hospitalization 2.49 1.77–3.50 <0.001
Treatment by cardiologist 2.11 1.30–3.41 0.002
Paroxysmal AF 3.52 2.35–5.27 <0.001
Palpitations 1.75 1.13–2.71 0.011
Fatigue 0.52 0.39–0.69 <0.001
Symptoms attributable to AF 2.40 1.61–3.58 <0.001
Mean heart rate 1.07 1.02–1.15 <0.001
HF 0.59 0.41–0.87 0.007
DCM 0.32 0.11–0.89 0.031
Mitral valve disease 0.60 0.41–0.89 0.013
Mean CHA2DS2-VASc score 0.86 0.78–0.94 0.002
AF; atrial fibrillation, OAC; oral anticoagulants, OR; odds ratio, CI; confidence interval, DCM; dilated cardiomyopathy HF; heart failure, DCM; dilated cardiomyopathy,
CHA2DS2-VASc; congestive heart failure, hypertension, age 75 years, diabetes, stroke/transient ischemic attack (TIA), vascular disease, age 65–74 years, sex category.
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M. Kozieł et al. / IJC Heart & Vasculature 26 (2020) 100461 7has not been driven by the individual patient stroke risk (i.e., the
CHA2DS2-VASc score value), whereas the use of rhythm control
strategy has been significantly associated with the presence of
AF-related symptoms and (iv) healthcare system-related factors
(such as centre type and location) significantly influenced the AF-
directed and stroke prevention strategies in patients with newly-
diagnosed AF.
4.1. Demographic, cardiovascular risk and AF-related profile of
patients with first-diagnosed AF
The mean age of patients with first-diagnosed AF in BALKAN-AF
registry and in other AF registries was similar [10,21,23]. The pro-
portion of patients with newly-diagnosed AF and hypertension,
diabetes mellitus and prior stroke was higher in the Balkan-AF reg-
istry than in the EURObservational Research Programme Atrial Fib-
rillation Pilot Registry (EORP-AF Pilot) [10], whereas patients with
first-diagnosed AF and coronary artery disease (CAD) were less
prevalent in the BALKAN-AF cohort. The prevalence of CAD, HF
and diabetes mellitus in patients with first-diagnosed AF is consis-
tent with datasets from the Euro Heart Survey on Atrial Fibrillation
[21], whereas prior stroke was less prevalent in the patients from
Euro Heart Survey nearly 15 years ago.
A similar mean CHA2DS2-VASc score and mean HAS-BLED score
to the patients with first-diagnosed AF from the BALKAN-AF reg-
istry was also seen in the EORP-AF Pilot Registry [10] and in the
most recent cohort of the FIELD-Atrial Fibrillation (GARFIELD-AF)
[24]. The GARFIELD-AF registry recruited patients with newly-
diagnosed ‘non-valvular’ AF and at least one risk factor for stroke.
4.2. Management of patients with first-diagnosed AF
In this study, patients with newly-diagnosed AF were more
often hospitalized because of AF, than patients with a history of
AF. This was also seen in the Central Registry of the German Com-
petence NETwork in Atrial Fibrillation (AFNET) [20]. Patients with
first-detected AF received OAC less often but were more likely to
receive single antiplatelet therapy alone than patients with previ-
ously diagnosed AF in the Balkan region. A similar pattern was
found in the AFNET registry [20]. The prevalence of management
with antiplatelet therapy was broadly similar among patients with
first-detected AF and patients with paroxysmal and persistent AF
in the EORP-AF Pilot Registry [10], whereas the management with
OAC was more frequent in persistent and permanent AF than in
first-diagnosed AF.
In our study, a rhythm control strategy was more often used in
patients with newly-diagnosed AF than in those with previously
diagnosed AF. According to guidelines, rhythm control strategy is
recommended for symptom improvement of AF patients [19].
Given that, the choice of rhythm control strategy should be based
on symptoms of AF, not on its duration. In one study [25], a rhythm
control strategy was also more often implemented in hospitalized
patients. This may be associated with more symptomatic status of
patients with first-diagnosed AF than patients with history of AF.
4.3. The use of OAC for stroke prevention in patients with first-
diagnosed AF
In our study about 60% of patients with newly-diagnosed AF
received OAC. The management with OAC for stroke prevention
in BALKAN-AF did not necessarily reflect the individual patient
stroke risk (i.e., the CHA2DS2-VASc score value) as indicated in
guidelines [26]. This is despite stroke prevention being one of the
cornerstones of optimal AF management [27]. Overall, the use of
VKA was lower, whilst the use of NOAC was slightly higher than
in other ‘real-world’ European registry [28]. We also observed sig-nificant country-specific differences in the use of antithrombotic
therapies that may help in identifying regions where stroke pre-
vention strategies need to be improved.
Despite evident indications for antithrombotic therapy, only
46% of patients with newly-diagnosed AF with CHA2DS2-VASc
score 2 was medicated with OAC. Moreover, 33% of patients with
CHA2DS2-VASc score of 0 used OAC, and only a minority of these
patients were scheduled for ECV or AF catheter ablation.
In the Balkan region, patients with hypertension, DCM were
more likely to receive OAC. Due to increased stroke risk of patients
with hypertension and DCM with congestive HF, they should be
considered for OAC use [19].
In our study, mitral valve disease was an independent predictor
of increased OAC use. Mitral stenosis is associated with the
increased risk of thrombo-embolism which may be related to the
low-flow in the left atrium [29]. The data regarding the risk of
stroke in AF patients with mitral regurgitation are controversial
[30], thus OAC should be initiated in AF patients with mitral regur-
gitation based on stroke risk factors using CHA2DS2-VASc score
[29].
In this study, history of bleeding was related to decreased OAC
use in patients with first-diagnosed AF. However, even high bleed-
ing risk score is not an excuse to withhold OACs where recom-
mended because the net clinical benefit (NCB) is even more
evident in this group of patients [31]. Bleeding risk which is a
highly dynamic process need to be re-assessed regularly
[26,31,32]. Modifiable risk factors should be treated optimally
where possible, and bleeding risk scores such as the HAS-BLED
score used appropriately to flag up high risk patients for early
review and follow-up [33].
4.4. The use of rhythm control strategy in patients with newly-
diagnosed AF
In the Balkans, symptoms attributable to AF including palpita-
tions were associated with the increased use of rhythm control
strategy in patients with newly-diagnosed AF. Management of AF
tends to be more symptom directed and patient centred what is
similar to other European registry [28]. Moreover, the implementa-
tion of rhythm control strategy is based on patient’s symptomatic
status [34]. This symptom-oriented approach follows an integrated
management of AF according to ABC pathway [35,36]. Interest-
ingly, the use of amiodarone was significantly higher in patients
with first-diagnosed AF than in patients with a history of AF
despite significantly higher prevalence of congestive heart failure
or left ventricle ejection fraction <40% in patients with previously
diagnosed AF. Possible reason is that amiodarone might have been
overused in the patient with first-diagnosed AF in the Balkan
region.
Mitral valve disease was an independent predictor of decreased
use of rhythm control strategy. Mitral regurgitation may facilitate
the occurrence of AF and make it worse to control with antiar-
rhythmic agents. However, mitral regurgitation was not correlated
with recurrent AF in the Atrial Fibrillation Follow-Up Investigation
of Rhythm Management (AFFIRM) study [37].
In our study, HF and DCM were associated with decreased use
of rhythm control strategy in the newly-diagnosed AF patients.
According to guidelines, rhythm control strategy should be chosen
in patients who develop HF with reduced ejection fraction, as a
result of tachycardiomyopathy, to make left ventricle function bet-
ter after restoration of sinus rhythm [19,38,39].
4.5. Healthcare system-related factors
In our study, patients treated in the capital city were more
likely to receive OAC, whilst management in a non-emergency cen-
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emergency centre and management by cardiologist were indepen-
dent predictors of the increased use of rhythm control strategy in
patients with newly-diagnosed AF. Higher likelihood of OAC use
in capital cities seems to be associated with their high concentra-
tion of tertiary health centres. In one study [25], similar influence
of centre location on antithrombotic therapy was showed.4.6. Knowledge gaps and unmet needs in the BALKAN region
Results of this survey may help to identify knowledge gaps in AF
management in daily clinical practice in the Balkans. Our findings
show that overall use of OAC is low (approx. 60%) in patients with
first-diagnosed AF in the Balkans. The overall use of OAC in
patients with newly-diagnosed AF was higher in EORP-AF Pilot
Registry [10], whereas was less prevalent in the older registries:
Euro Heart Survey and AFNET [20,21]. In our study, the association
of OAC use with individual stroke risk is weak. Unfortunately,
despite high proportion of patients with newly-diagnosed AF with
increased risk of stroke, 11.9% of patients receive no antithrom-
botic therapy and 19.0% receive single antiplatelet therapy alone.
These findings implicate that the management of patients with
AF at risk of stroke is not adherent to guidelines [19].
In this study, paroxysmal AF was negatively associated with
OAC use. Importantly, ischaemic stroke may occur as commonly
in paroxysmal AF as in permanent AF [40]. However, in one study,
yearly rates of ischaemic strokes were 2.1% for paroxysmal AF and
4.2% for permanent AF [41]. Indeed, patients with paroxysmal AF
and conventional stroke risk factors have indications to OAC [19].
Consequently, the pattern of AF should not affect the management
with OAC. The use of antithrombotic therapy was also associated
with the health center location and was increased in capital cities.
Differences were observed in the management with rhythm con-
trol strategy according to physician specialty because cardiologists
used rhythm control more often than other specialists.
Holistic treatment of patients with first-diagnosed AF should
help to solve unmet clinical needs including underuse of OAC,
the suboptimal association of OAC with individual stroke risk and
limited access to rhythm control strategy. Moreover, integrated AF
care requires services accessible for all patients and cooperation
between various medical specialists [19].4.7. Limitations
Our study has a few limitations including the observational
study design and lack of follow-up data to assess outcomes. Possi-
ble selection bias may occur because of different healthcare setting
in participating countries. Moreover, information about patient/
prescriber treatment preferences is lacking. Also, data from the
survey are limited to the Balkan population, but this is the largest
AF dataset from this region. Moreover, physicians were aware that
their recommendations on diagnostic assessment and manage-
ment would be recorded. Registries are likely to attract selected
highly motivated patients and their treatment at enrolment may
express higher compliance. However, because of enrolment of con-
secutive patients, the likelihood for a physician to enroll mainly
patients with higher compliance is limited.5. Conclusions
In BALKAN-AF survey, patients with newly-diagnosed AF were
more often hospitalized, less often received OAC and were more
likely to receive SAPT alone. The use of OAC for stroke prevention
has not been driven by the individual patient stroke risk.Funding source
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